CluePoints announced the launch of its new business intelligence platform, BEYOND. Designed to encompass more than just early risk detection, this extended visualization solution allows CluePoints Sponsor and CRO users to explore areas of interest in one integrated business intelligence system. The analytics tool allows users to confidently certify the quality and integrity of data whilst ensuring patient safety and regulatory compliance. Learn how the BEYOND business intelligence platform can help you reach your clinical trial goals here.
“We are very excited to launch our novel business intelligence platform as an extension of our ongoing commitment to helping companies identify, assess, plan, mitigate, monitor and analyze risk across all elements of clinical trial management. It is a key milestone in our strategy to become a knowledge company and we would like to thank those sponsors who have collaborated to bring this vision to life,” Francois Torche, Co-Founder & Chief Executive Officer of CluePoints said.
As the industry realizes the benefits of Risk-Based Monitoring (RBM) and Risk-Based Quality Management (RBQM), users are looking for ways to extend the way they drill-down into risks and focus on what matters most within their studies. The comprehensive nature of the analytics offered within this novel business intelligence platform gives all users the data exploration tools and personalized visualizations they need to test hypotheses and drive critical thinking. Within one unique platform, risk signals can be identified, and an embedded Issues and Actions Management system ensures that all evidence is fully documented and accessible. This guarantees full compliance with ICH E6 (R2) and other global regulatory requirements throughout the lifecycle of the clinical trial.
This all-encompassing platform offers an exclusive combination of both supervised and unsupervised data surveillance techniques that enables users to test what they think they know, as well as what they could not possibly know or suspect.